Neuro-Sys - Solutions/Service Company
pharmatechoutlook

Pharma Tech Outlook: Pharma Tech Magazine

Neuro-Sys: Pioneering R&D in the Neurodegenerative Diseases Field

Follow Neuro-Sys on :

Yann Jaudouin, CEO, Neuro-SysYann Jaudouin, CEO
The World Health Organization (WHO) classifies neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, as one of the greatest health threats today. And although significant methods of its diagnosis and treatment exist, the results haven’t been promising. For instance, the most effective therapies leveraged for the treatment of Parkinson’s still cause deteriorating side effects like psychosis, dyskinesias, and motor fluctuations. Also, since these therapies don’t stop the underlying decline and death of the brain cells completely, the disease continues to progress. Thus, it is imperative today to develop new therapeutic avenues to make headway in the treatment of neurodegenerative diseases.

On that front, pre-clinical models (both in vitro and in vivo) are vital in aiding the research community to shed light on the mechanisms underlying these neurodegenerative diseases and discover promising treatments in the primary stages of drug development. And, amid a pool of research and development (R&D) organizations at the forefront of this notable quest, a name worth mentioning is Neuro-Sys. Today, as a research-intensive and innovative contract research organization (CRO), Neuro-Sys is making great strides in the neurodegenerative diseases drugs market. Their expertise in identifying and discovering lead compounds has aided many pharmaceutical laboratories, biotech companies, and academic organizations to discover new treatment options for many neurodegenerative diseases.

The CRO Pivoted in Science and Research

Neuro-Sys was founded in 2013 by a group of esteemed pharmacists and neuro-pharmacologists specializing in neurodegenerative diseases to meet the substantial demand for contract research services in treating central nervous system (CNS) and peripheral nervous system (PNS) disorders. The firm has drastically improved pharmacology efficacy over the years. Today, leaning on their esteemed in-house research, Neuro-Sys provides unique in vitro and in vivo pre-clinical models that can accurately determine the lead compounds’ pharmacological profiling and explore their underlying action mechanism to benefit the treatment of neurodegenerative diseases.

Yann Jaudouin, the CEO at Neuro-Sys, affirms that its expertise in science and research has enabled them to become a tough leader in pharmacology and neuro-development. “We undertake a diverse range of science and research programs to decode the various reasons behind a neuron’s progressive loss of structure and function.

Neuro-Sys was founded in 2013 by a group of esteemed pharmacists and neuro-pharmacologists specializing in neurodegenerative diseases to meet the substantial demand for contract research services in treating central nervous system (CNS) and peripheral nervous system (PNS) disorders


Based on the results, we formulate a detailed plan to develop robust in vitro and in vivo pre-clinical models for neurodegenerative diseases,” says Jaudouin. In that regard, Neuro-Sys’ capability in developing pre-clinical models that mimic the pathology of diseases, such as Alzheimer’s and Parkinson’s, is unparalleled in the domain.

Besides modelling the pre-clinical models for drug discovery, Neuro-Sys is also adept at designing and realizing pre-clinical and clinical research programs for their clients to identify and develop new leading compounds. For the in-house R&D, Neuro-Sys has a very competent team of dedicated researchers, including best-in-breed physicians, neurologists, and scientists from the pharma and biotech backgrounds, headed by Dr Noelle Callizot, CSO at Neuro-Sys, and Dr Alexandre Henriques, the company’s pharmacology director . This team of experts can be entirely relied upon for advice and supervision on every step of the pharmaceutical development process.

Notably, to complement the expertise, Neuro-Sys leverages state-of-the-art laboratory equipment. The company offers fully automated pharmacological platforms, which allows a high frequency of screening and better reproducibility of studies. Meanwhile, the company also offers other cutting-edge equipment, including an automated histology platform with very powerful confocal microscopy, brand new video tracking systems, and so on.

Basking in the glory of such competencies, Neuro-Sys has established an exceptionally diverse clientele in the domain that includes big and small pharmaceutical laboratories and biotech startups, along with academic organizations in Europe and the U.S. Yann Jaudouin further cites a recent client interaction as an example. “One of our clients based in the U.S. asked us to develop a particular molecular model that didn’t exist in the market for the drug development of a certain illness”. Neuro-Sys closely collaborated with the client and successfully developed the molecular model, thus the drug will soon be introduced at the clinical level.

At this juncture, having carved a niche for itself in the neurodegenerative field, Neuro-Sys is all set to expand its capabilities with a particular focus on in vivo models. They are planning to double the size of their scientific team and laboratories by mid-2022. “We will continue to deliver exceptional and innovative pre-clinical in vivo and in vitro models to meet the unique needs of our clients in the neurodegenerative diseases market,” concludes Yann Jaudouin.
Share this Article:
Top 10 Pharma Outsourcing Service Companies - 2021

Company
Neuro-Sys

Headquarters
Gardanne, France Boston, MA

Management
Yann Jaudouin, CEO

Description
Leaning on their esteemed in-house research and state-of-the-art equipment, Neuro-Sys provides unique in vitro and in vivo pre-clinical models that can accurately determine the lead compounds’ pharmacological profiling and explore their underlying action mechanism to benefit the treatment of neurodegenerative diseases, such as Alzheimer’s and Parkinson’s. Besides modeling the pre-clinical models for drug discovery, Neuro-Sys is also adept at designing and developing pre-clinical and clinical research programs for their clients to identify and develop new leading compounds. For the in-house R&D, Neuro-Sys has a very competent team of dedicated researchers, including best-in-breed physicians, neurologists, and scientists from the pharma and biotech backgrounds, headed by Dr Noelle Callizot, CSO at Neuro-Sys, and Dr Alexandre Henriques, the company’s director of pharmacology.

Neuro-Sys